Challenge to the Development of Molecular Targeted Therapy against a Novel Target Candidate Identified by Antibody Proteomics Technology

• Nagano Kazuya

  Laboaratoy of Toxicology and Safety Sciences, Graduate School of Pharmaceutical Sciences, Osaka University National Institutes of Biomedical Innovation, Health and Nutrition

Bibliographic Information

Other Title

• 抗体プロテオミクス技術による新規治療標的候補の同定と分子標的治療薬開発への挑戦
• Symposium Review 抗体プロテオミクス技術による新規治療標的候補の同定と分子標的治療薬開発への挑戦
• Symposium Review コウタイ プロテオミクス ギジュツ ニ ヨル シンキ チリョウ ヒョウテキ コウホ ノ ドウテイ ト ブンシ ヒョウテキ チリョウヤク カイハツ エ ノ チョウセン

Abstract

  Disease proteomics that systemically analyzes and identifies differentially expressed proteins between healthy and diseased samples is a potentially useful approach for obtaining target proteins for drug development. To date, however, very few target proteins have been identified from this field. A key issue that remains to be resolved is how to correctly identify target proteins from a number of potential candidates. To circumvent this problem, we have developed “antibody proteomics technology” in which a single chain Fv phage antibody library is utilized for proteome analysis. Here, we describe the application of this technology by primarily focusing on Eph receptor A10 (EphA10), a novel breast cancer-related protein that is a promising target for antibody drugs. To establish an effective and safe targeted cancer therapy, it is important that the target is specifically expressed in cancer tissues. Therefore, we attempted to analyze the EphA10 expression profiles. Tissue microarray analysis showed that EphA10 was expressed in all subtypes of breast cancer containing triple negative breast cancer cases. On the other hand, EphA10 was only expressed in testis tissue among 36 kinds of normal tissues. Thus, EphA10 could be a highly cancer-specific protein, making it a promising target for female breast cancer patients. Finally, we examined the anti-tumor effect by anti-EphA10 antibody, aiming for the development of a novel EphA10 targeting therapy. Administration of the antibody showed that tumor volumes were significantly inhibited. Our results suggest that targeting EphA10 in breast cancer cases might be a promising new form of therapy.<br>

Journal

• YAKUGAKU ZASSHI

  YAKUGAKU ZASSHI 136 (2), 145-149, 2016-02-01

  The Pharmaceutical Society of Japan

Keywords

• disease proteomics
• molecular targeted therapy
• antibody proteomics
• Eph receptor A10

Details

• CRID: 1390001206128303616
• NII Article ID: 130005121468
• NII Book ID: AN00284903
• DOI: 10.1248/yakushi.15-00226-1
• ISSN: 13475231
• ISSN: 00316903
• NDL BIB ID: 027083825
• PubMed: 26831784
• Web Site: http://id.ndl.go.jp/bib/027083825
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I027083825
• Web Site: https://www.jstage.jst.go.jp/article/yakushi/136/2/136_15-00226-1/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2016205938
• Text Lang: ja
• Data Source:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed